Airway inflammation in COPD: progress to precision medicine
ChristopherÂ Brightling,Â NeilÂ Greening
European Respiratory JournalÂ 2019Â 54:Â 1900651;Â DOI:Â 10.1183/13993003.00651-2019
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent feature of COPD and is implicated in the pathogenesis and progression of COPD, but anti-inflammatory therapy is not first-line treatment. The inflammation has many guises and phenotyping this heterogeneity has revealed different patterns. Neutrophil-associated COPD with activation of the inflammasome, T1 and T17 immunity is the most common phenotype with eosinophil-associated T2-mediated immunity in a minority and autoimmunity observed in more severe disease. Biomarkers have enabled targeted anti-inflammatory strategies and revealed that corticosteroids are most effective in those with evidence of eosinophilic inflammation, whereas, in contrast to severe asthma, response to anti-interleukin-5 biologicals in COPD has been disappointing, with smaller benefits for the same intensity of eosinophilic inflammation questioning its role in COPD. Biological therapies beyond T2-mediated inflammation have not demonstrated benefit and in some cases increased risk of infection, suggesting that neutrophilic inflammation and inflammasome activation might be largely driven by bacterial colonisation and dysbiosis. Herein we describe current and future biomarker approaches to assess inflammation in COPDÂ and how this might reveal tractable approaches to precision medicine and unmask important hostâ€“environment interactions leading to airway inflammation.
Airway inflammation drives COPD, but corticosteroids only work in those with eosinophilic inflammation. There is a need to better understand the patterns of inflammation, the reason for its persistence and the opportunities for new treatments.Â http://bit.ly/2VIOo9w
Number 5 in the series “Controversies in COPD: What Can be Done to Move the Field Forward?” Edited by D.D. Sin
Previous articles in this series: No. 1:Â Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement.Â Eur Respir JÂ 2018; 52: 1801261.Â No. 2:Â Washko GR, Parraga G.Â COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging.Â Eur Respir JÂ 2018; 52: 1801570.Â No. 3:Â Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important?Â Eur Respir JÂ 2018; 52: 1801448.Â No. 4:Â Leung JM, Obeidat M, Sadatsafavi M,Â etÂ al. Introduction to precision medicine in COPD.Â Eur Respir JÂ 2019; 53: 1802460.
Conflict of interest: C.Â Brightling reports grants and personal fees (paid to institution) for consultancy from MedImmune, AstraZeneca, GlaxoSmithKline, Roche/Genentech, Novartis, Chiesi, Pfizer and Mologic, personal fees (paid to institution) for consultancy from Teva, Sanofi, Regeneron, Glenmark and Vectura, outside the submitted work.
Conflict of interest: N.Â Greening reports personal fees for consultancy and non-financial support for travel from AstraZeneca, Chiesi and Boehringer Ingelheim, grants, personal fees for consultancy and non-financial support for travel from GlaxoSmithKline, outside the submitted work.
- ReceivedÂ March 31, 2019.
- AcceptedÂ April 25, 2019.
- Copyright Â©ERS 2019